| Characteristic | Female N = 191 |
Male N = 881 |
|---|---|---|
| Total dose (daily, milligrams) | ||
| 0.25 | 2 / 8 (25%) | 0 / 32 (0%) |
| 0.84 | 1 / 8 (13%) | 0 / 32 (0%) |
| 10 | 0 / 8 (0%) | 15 / 32 (47%) |
| 11.25 | 1 / 8 (13%) | 0 / 32 (0%) |
| 15 | 0 / 8 (0%) | 2 / 32 (6.3%) |
| 19 | 1 / 8 (13%) | 0 / 32 (0%) |
| 2.5 | 1 / 8 (13%) | 1 / 32 (3.1%) |
| 20 | 1 / 8 (13%) | 3 / 32 (9.4%) |
| 30 | 0 / 8 (0%) | 1 / 32 (3.1%) |
| 40 | 0 / 8 (0%) | 2 / 32 (6.3%) |
| 5 | 1 / 8 (13%) | 6 / 32 (19%) |
| 60 | 0 / 8 (0%) | 1 / 32 (3.1%) |
| 7.5 | 0 / 8 (0%) | 1 / 32 (3.1%) |
| (Missing) | 11 | 56 |
| Drug | ||
| 1 / 19 (5.3%) | 0 / 88 (0%) | |
| Loniten | 1 / 19 (5.3%) | 3 / 88 (3.4%) |
| Lonolox | 0 / 19 (0%) | 4 / 88 (4.5%) |
| Lonolox (Minoxidil) | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Mens Rogaine Unscented Formula | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Minoxidil | 14 / 19 (74%) | 73 / 88 (83%) |
| Minoxidil (Minoxidil 10mg Tab) | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Minoxidil (Minoxidil 2 5mg Tab) | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Minoxidil (Watson Laboratories) | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Minoxidil Extra Strength (For Men) | 0 / 19 (0%) | 2 / 88 (2.3%) |
| Minoxidil Topical Solution | 0 / 19 (0%) | 2 / 88 (2.3%) |
| Regaine | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Regaine Extra Strength-Mens (5%) | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Country which reported the AE | ||
| Australia | 0 / 19 (0%) | 2 / 88 (2.3%) |
| Austria | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Canada | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Colombia | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Denmark | 0 / 19 (0%) | 1 / 88 (1.1%) |
| France | 3 / 19 (16%) | 0 / 88 (0%) |
| Germany | 2 / 19 (11%) | 5 / 88 (5.7%) |
| Japan | 0 / 19 (0%) | 3 / 88 (3.4%) |
| South Africa | 1 / 19 (5.3%) | 0 / 88 (0%) |
| Spain | 0 / 19 (0%) | 1 / 88 (1.1%) |
| Switzerland | 2 / 19 (11%) | 1 / 88 (1.1%) |
| United Kingdom | 0 / 19 (0%) | 4 / 88 (4.5%) |
| United States | 9 / 19 (47%) | 70 / 88 (80%) |
| Indication for use | ||
| Alopecia | 2 / 13 (15%) | 3 / 64 (4.7%) |
| Blood pressure | 0 / 13 (0%) | 1 / 64 (1.6%) |
| Blood pressure abnormal | 0 / 13 (0%) | 1 / 64 (1.6%) |
| Blood pressure management | 0 / 13 (0%) | 1 / 64 (1.6%) |
| Cardiac operation | 0 / 13 (0%) | 1 / 64 (1.6%) |
| Chronic kidney disease | 0 / 13 (0%) | 1 / 64 (1.6%) |
| Essential hypertension | 1 / 13 (7.7%) | 1 / 64 (1.6%) |
| Hypertension | 6 / 13 (46%) | 46 / 64 (72%) |
| Hypertonia | 0 / 13 (0%) | 3 / 64 (4.7%) |
| Malignant renal hypertension | 1 / 13 (7.7%) | 0 / 64 (0%) |
| Product used for unknown indication | 3 / 13 (23%) | 6 / 64 (9.4%) |
| (Missing) | 6 | 24 |
| Rechallenge | ||
| Does not apply | 8 / 12 (67%) | 19 / 30 (63%) |
| Negative rechallenge | 2 / 12 (17%) | 1 / 30 (3.3%) |
| Unknown | 2 / 12 (17%) | 10 / 30 (33%) |
| (Missing) | 7 | 58 |
| Dechallenge | ||
| Does not apply | 2 / 13 (15%) | 2 / 53 (3.8%) |
| Negative dechallenge | 1 / 13 (7.7%) | 1 / 53 (1.9%) |
| Positive dechallenge | 5 / 13 (38%) | 45 / 53 (85%) |
| Unknown | 5 / 13 (38%) | 5 / 53 (9.4%) |
| (Missing) | 6 | 35 |
| Reporter's occupation | ||
| Consumer | 4 / 17 (24%) | 8 / 84 (9.5%) |
| Lawyer | 0 / 17 (0%) | 1 / 84 (1.2%) |
| Other Health Professional | 3 / 17 (18%) | 33 / 84 (39%) |
| Pharmacist | 2 / 17 (12%) | 23 / 84 (27%) |
| Physician | 8 / 17 (47%) | 19 / 84 (23%) |
| (Missing) | 2 | 4 |
| Weight,kilograms | 56.93 (38.09) | 89.93 (24.66) |
| (Missing) | 8 | 47 |
| Age,years | 43.82 (31.17) | 55.64 (15.27) |
| (Missing) | 4 | 8 |
| 1 n / N (%); Mean (SD) | ||